Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer


Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Cisplatin/Gemcitabine in Patients With Metastatic or Locally Advanced Urothelial Cancer Without Prior Systemic Therapy


Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for urinary tract cancer.


Randomized phase III trial to compare the effectiveness of cisplatin plus gemcitabine with or without paclitaxel in treating patients who have stage IV urinary tract cancer.

Study Status: Completed


Condition Intervention Phase
Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter
Urethral Cancer
Drug: cisplatin
Drug: gemcitabine hydrochloride
Drug: paclitaxel
Phase 3

Verified by European Organisation for Research and Treatment of Cancer - EORTC June, 2013

Sponsored by: European Organisation for Research and Treatment of Cancer - EORTC
Information provided by: European Organisation for Research and Treatment of Cancer - EORTC identifier: NCT00022191

Study Type: Interventional

Study Design: Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195-9001
United States

Joaquim Bellmunt, MD, PhD., Study Chair
Stephane Culine, MD., Study Chair
Michael Leahy, MBChB, FRACP, FRCP, FRC Path., Study Chair
Christoph Zielinski, MD., Study Chair
Malcolm J. Moore, MD., Study Chair
David C. Smith, MD., Study Chair
Andreas Boehle, MD., Study Chair
Jose Baselga, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site